Reflux disease can severely impact upon quality-of-life and lead to complications, including ulceration of the oesophagus. It is often controlled with self-help measures and medication. However, sometimes surgery is recommended. The current standard surgical treatment is called a fundoplication. This operation is carried out through keyhole (laparoscopic) surgery, and tightens the lower oesophagus to prevent reflux. Fundoplication is very safe and improves the quality-of-life of most patients. However, many patients have gas bloating, difficulty swallowing and recurrence of their reflux symptoms. As an alternative, some surgeons use a device called LINX, using a keyhole procedure. LINX is a magnetic device that wraps around the lower oesophagus to prevent reflux. Studies suggest that LINX may cause fewer complications, with a similar improvement in quality-of-life. However, there is a need for better evidence to compare LINX with fundoplication in the surgical treatment of reflux disease. GOLF is a multi-centre study designed which to determine if LINX achieves similar reflux control and improves symptoms compared to fundoplication. GOLF measures: (1) quality of life,(2) surgical complications, including need for additional treatment, (3) financial cost-effectiveness and (4) objectively measure the presence of acid that has refluxed into the lower oesophagus. GOLF aims randomise 460 patients to receive fundoplication or the LINX device. It will be conducted across at least 16 UK and 7 European specialist surgical centres. All participants will be followed up at 6 weeks, 6, 12 and 24 months to assess which treatment offers the best results after surgery. A quality assurance programme within participating centres will ensure that procedures are completed to a high-quality standard. Study results will incorporate a patient and public involvement programme, which will inform national and international guidelines for the surgical treatment of reflux disease.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
460
Participants randomised to laparoscopic or robotic magnetic sphincter augmentation (LINX procedure) will receive surgical treatment under general anaesthesia, with placement of the LINX device around the distal oesophagus. The LINX device comprises titanium beads with magnets in the centre.
Participants randomised to laparoscopic or robotic fundoplication will receive surgical treatment for managing GORD including a total or partial fundic wrap behind or in front of the distal oesophagus and gastro-oesophageal junction.
Guy's and St Thomas's NHS Foundation Trust, Guy's and St Thomas's Hospital
Oxford, Oxfordshire, United Kingdom
RECRUITINGImperial College Healthcare NHS Trust, St Mary's Hospital
Oxford, Oxfordshire, United Kingdom
RECRUITINGLeeds Teaching Hospitals NHS Trust, St James's University Hospital
Oxford, Oxfordshire, United Kingdom
RECRUITINGOxford University Hospitals NHS Foundation Trust, Churchill Hospital
Oxford, Oxfordshire, United Kingdom
RECRUITINGUniversity Hospital Southampton NHS Foundation Trust
Oxford, Oxfordshire, United Kingdom
RECRUITINGSymptomatic GORD and health-related quality of life (HRQL) assessed using the GORD-HRQL questionnaire
Time frame: 24 months following surgery
Prevalence of gas bloating measured using participant-reported outcomes/GORD-HRQL and Foregut Symptom Questionnaire
Time frame: 24 months postoperatively
Prevalence of inability to belch measured using participant-reported outcomes/GORD-HRQL and Foregut Symptom Questionnaire
Time frame: 24 months postoperatively
Prevalence of symptomatic GORD, inability to belch and gas bloating measured using participant-reported outcomes/GORD-HRQL and Foregut Symptom Questionnaire
Time frame: 6 weeks, 6 and 12 months after surgery
Severity of dysphagia and regurgitation measured using participant-reported outcomes/GORD-HRQL questionnaire
Time frame: 6 weeks, 6, 12 and 24 months postoperatively
Global HRQL measured using participant-reported outcomes/EQ-5D-5L questionnaire
Time frame: 6 weeks, 6, 12 and 24 months postoperatively
Utilisation of anti-GORD medications measured using participant-reported outcomes/questionnaire
Time frame: 6 weeks, 6, 12 and 24 months postoperatively
24-hour pH measurement measured using participant's medical records/24-hour pH measurement or BRAVO test
Time frame: 12 months postoperatively
Postoperative complication rates, including reoperation and endoscopic reintervention, measured using participant's medical records/postoperative outcomes
Time frame: 30-day, 90-day, 12 and 24-month
Cost-effectiveness of both treatments as measured by incremental cost per quality-adjusted life year (QALY)
Time frame: 6 weeks, 6, 12 and 24 months postoperatively
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.